Prognosis

Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes

Retrieved on: 
Tuesday, August 17, 2021
RW, Company, Standard of care, University, Observation, Adjuvant, Journal of Thoracic Oncology, Cancer, Prognosis, EGFR, Large-cell lung carcinoma, Biomarker, West Pharmaceutical Services explosion, Surgeon, Diagnosis, GLOBE, Medical Affairs Bureau, Decision-making, Physician, Science, Research, Woodward, Lung cancer, IIA, Tumor microenvironment, OCX, Â, Biology, Risk, Patient, NCCN, Hospital, Oncocyte, VP, Recurrence, Neoplasm, Hospital of the University of Pennsylvania, Pharmaceutical industry, Medical imaging

IRVINE, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to provide clear insights that inform critical decisions in cancer treatment, announced today the launch of a nationwide, prospective, real-world (RW) registry for patients with potentially curable early-stage lung cancer. The study is entitled the Predictive Assay for Decision Making in Adjuvant Therapy (PADMA) Registry.

Key Points: 
  • This registry was created to collect data that may demonstrate the impact of biomarker-guided treatment decisions on patients with completely resected stage I and IIA non-squamous non-small cell lung cancer across multiple academic and community cancer centers in the United States.
  • Biomarker tests are playing an increasingly important role in guiding cancer treatment.
  • The PADMA Registry, which utilizes Oncocytes DetermaRxTM test, will be the first RW initiative to evaluate the use of biomarkers in early-stage lung cancer.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.

Global microRNA (miRNA) Market Analysis Report 2021: Focus on Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 17, 2021
Infectious Diseases, Health, Oncology, Blood pressure, Packera aurea, Growth, Therapy, MicroRNA, Adoption, Prognosis, Fluid mechanics, Diagnosis, Biomarker, Research, Bipolar II disorder, Asia, Investment, Mirna, Neurodegeneration, Hypertension, Genomics, Goal, NGS, Proteomics, Medical imaging, Pharmaceutical industry

The "microRNA Market Share, Size, Trends, Industry Analysis Report, By Product; By Services; By Application; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "microRNA Market Share, Size, Trends, Industry Analysis Report, By Product; By Services; By Application; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The rising adoption of microRNA as a biomarker is driving the market.
  • Moreover, growing interest in liquid-based biopsies has further led to its increased importance in biomarker discovery and further development.
  • In addition, a market study has also paved several computational tools to predict the relation between miRNA and its target microRNA.

Methylome Profiling and Biomarker Discovery Using MeDIP-Seq from Liquid Biopsy Samples, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, August 17, 2021
Industry, DNA methylation, Cancer, Prognosis, Risk assessment, Method, Harvard Medical School, Liquid biopsy, DNA, CpG, Immunoprecipitation, Food, Oncology, Dana–Farber Cancer Institute, Classification, Department, Nucleic acid thermodynamics, Medical imaging

CfDNA methylation profiling provides several advantages over the methods based on somatic mutations.

Key Points: 
  • CfDNA methylation profiling provides several advantages over the methods based on somatic mutations.
  • DNA methylation is a tissue-specific and stable epigenetic mark that allows one to determine the tissue of origin.
  • Register for this webinar to hear a discussion about the applications and analysis of cfMeDIP-seq in liquid biopsy with a special interest in cancer detection.
  • For more information, or to register for this event, visit Methylome Profiling and Biomarker Discovery Using MeDIP-Seq from Liquid Biopsy Samples.

Castle Biosciences Presents New Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the 2021 American Academy of Dermatology (AAD) Summer Meeting

Retrieved on: 
Monday, August 16, 2021
Oncology, Health, Genetics, Research, Science, Biotechnology, Baylor University Medical Center, Overalls, SCC, Frontier Organic Research Farm Botanical Garden, Recurrence, ROR, NCCN, American Academy of Dermatology, First, American Academy, Appropriate use criteria, RFS, MSS, National Comprehensive Cancer Network, American Joint Committee on Cancer, SLN, Risk, Kaplan–Meier estimator, Classification, Metastasis, Prognosis, N-420 road (Spain), Patient, List of life sciences, AAD, Physician, Nasdaq, Sentinel lymph node, GEP, BWH, CSCC, Medical device, Medical imaging, Risk management, Silviculture, DecisionDx-Melanoma, DecisionDx-SCC, Castle Biosciences, DECISIONDX-MELANOMA, DECISIONDX-SCC, CASTLE BIOSCIENCES

Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced recent presentations on two of its skin cancer gene expression profile tests at the 2021 American Academy of Dermatology (AAD) Summer Meeting, held Aug. 5-8, 2021.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced recent presentations on two of its skin cancer gene expression profile tests at the 2021 American Academy of Dermatology (AAD) Summer Meeting, held Aug. 5-8, 2021.
  • The study demonstrated that DecisionDx-Melanoma added significant prognostic value for a patient beyond traditional staging, said Taylor.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
  • Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make.

Deep Bio's AI-based Antibody Optimization Platform Applied to Parkinson's Disease

Retrieved on: 
Friday, August 13, 2021
Time, Drug discovery, Prostate, Parkinson's disease, CEO, Pathology, University, Deep learning, Medicine, Partnership, Research, Laboratory, Antibody, Prognosis, Patient, VisionAire 500K, Medical device, Technology, H&E, AI, IVD, Diagnosis, MFDS, Workload, R, Marie Cassidy, Prostate cancer, Medical imaging

The R&D collaboration aims to find the most optimized antibody by applying Deep Bio's AI technology to promising candidates.

Key Points: 
  • The R&D collaboration aims to find the most optimized antibody by applying Deep Bio's AI technology to promising candidates.
  • The antibody under study, if successful, has the potential to become an effective treatment option for patients with Parkinson's disease.
  • Utilizing our AI-based algorithm will dramatically reduce the time and cost for drug optimization," said the CEO of Deep Bio.
  • Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics.

Widowers more likely to be diagnosed with advanced prostate cancer

Retrieved on: 
Thursday, August 12, 2021
European Journal, Prostate cancer, Marriage, Diagnosis, Incidence, Friends, Marital status, American Cancer Society, MONTRAL, Social environment, Family, Salmon, Varennes-en-Argonne, Canadian Cancer Society, Public, Grief, Cancer, European Journal of Epidemiology, Canadian Institutes of Health Research, Institute, Student, Doctor of Philosophy, Man, Death, Social isolation, INRS, Prognosis, Professor, Risk, Research, Interdisciplinarity, Disease, Widow, Diet, Medical imaging, Pharmaceutical industry

PhD student Charlotte Salmon and Professor Marie-lise Parent of the Institut national de la recherche scientifique (INRS) have shown that widowers are more likely to be diagnosed with advanced prostate cancer.

Key Points: 
  • PhD student Charlotte Salmon and Professor Marie-lise Parent of the Institut national de la recherche scientifique (INRS) have shown that widowers are more likely to be diagnosed with advanced prostate cancer.
  • The link was first identified following analysis of 12 studies from the international consortium PRACTICAL comparing 14,000 men newly diagnosed with prostate cancer and 12,000 healthy men.
  • "This large group of subjects showed us that widowers were at risk of being diagnosed later than married men or men in relationships.
  • The Canadian Cancer Society estimated that, in 2020, 23,300 men in Canada would be diagnosed with prostate cancer.

DGAP-News: Adler Group S.A.: Standard and Poor's confirms stable outlook for Adler Group's credit rating, reflecting performance of Adler's business

Retrieved on: 
Wednesday, August 11, 2021
Consus, Housing, S&P, DGAP, S&P Global Ratings, News, BB, ESG, Group, Mission statement, Rodney Adler, Prognosis, Interior design, Security (finance), Management

Adler Group S.A.: Standard and Poor's confirms stable outlook for Adler Group's credit rating, reflecting performance of Adler's business

Key Points: 
  • Adler Group S.A.: Standard and Poor's confirms stable outlook for Adler Group's credit rating, reflecting performance of Adler's business
    The issuer is solely responsible for the content of this announcement.
  • Standard and Poor's confirms stable outlook for Adler Group's credit rating, reflecting performance of Adler's business
    Berlin, 11 August 2021 - Adler Group SA ("Adler") is pleased to announce that the international rating agency Standard and Poor's (S&P) has affirmed the "BB" credit rating of Adler Group S.A. and confirmed the outlook for the rating as "stable".
  • S&P expects the operating performance of Adler's business to be stable over the next 12 to 18 months, and also noted the group's positive refinancing position.
  • Maximilian Rienecker, Co-CEO of the Adler Group, explains: "We are very pleased with the position of the business and our financial situation.

Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant

Retrieved on: 
Wednesday, August 11, 2021
Squamous cell carcinoma, Smoker, Lung cancer, DNA, CSE, AGN, NCI, PARP, ERK, GLOBE, Prognosis, Dartmouth College, Pharmaceutical industry

48 hr incubation with Ifenprodil doses

Key Points: 
  • 48 hr incubation with Ifenprodil doses 106M.
  • We are very pleased to be expanding our Ifenprodil cancer research program to include SCLC, said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
  • We also welcome Dr. William North to help us lead the investigation of Ifenprodils potential as a new non-toxic cancer therapy.
  • The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils and certain types of cancer cells.

Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, August 11, 2021
CMC, Glycogen storage disease type V, IPO, Exercise intolerance, Muscle weakness, Degenerative disease, Myopathy, Safety, Company, Patient, PGIC, Â, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, MFIS, Deafness, DNA, McArdle, Death, Conference, Ultragenyx, Gene, Tissue, Heart, Disorder, Parallel Walk Test, Clinical trial, Brain, Home After Three Months Away, Adult, STRIDE, Research, Lists of diseases, Metabolism, Nasdaq, Mitochondrion, History, Investment, Adenosine triphosphate, GLOBE, PMM, ATP, Prognosis, Severe cognitive impairment, SVB Leerink, Pharmaceutical industry, Animal

IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter endedJune 30, 2021and provided an update on its clinical programs.

Key Points: 
  • IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter endedJune 30, 2021and provided an update on its clinical programs.
  • The second quarter of 2021 was highly productive for the Reneo team as we launched the international STRIDE study, completed enrollment of the McArdle disease study, and made substantial progress in our long-chain fatty acid oxidation disorders studies, said Gregory J. Flesher, President and Chief Executive Officer of Reneo Pharmaceuticals.
  • The company had $167.3 million in cash, cash equivalents and short-term investments as of June 30, 2021.
  • Research and development expenses for the three months ended June 30, 2021 were $6.3 million, compared to $2.8 million for the three months ended June 30, 2020.

Biomerica Announces Notice of Allowance for Patent on Product used to Diagnose and Treat Depression

Retrieved on: 
Wednesday, August 11, 2021
Patient, Depression, Technology, Sale, Private Securities Litigation Reform Act, Attention deficit hyperactivity disorder predominantly inattentive, Environment, Product, GLOBE, Diarrhea, Company, Clinical professor, Physician, Disability, Trial of the century, Mixed anxiety–depressive disorder, Migraine, Bloating, Gastroesophageal reflux disease, IBS, University of Texas Health Science Center at San Antonio, Ulcerative colitis, NASDAQ, Houston Methodist Hospital, Texas Medical Center, Research, Prognosis, Systematic review, Mayo Clinic, Milk, Inflammation, Egg, Health, Patent, Review, Immune system, Indigestion, Biomedical technology, Irritable bowel syndrome, Constipation, FDA, GERD, Quality of life, Pain, COVID-19, Mental health, Prevalence, Diet, University, Disease, CPT, Salmon, Pharmaceutical industry, Medical device, Gum arabic

Research performed at Biomerica that formed the basis for claims in this allowed depression-related patent, indicates that certain foods are linked to an elevated adverse immune response in patients with depression.

Key Points: 
  • Research performed at Biomerica that formed the basis for claims in this allowed depression-related patent, indicates that certain foods are linked to an elevated adverse immune response in patients with depression.
  • For example, Biomerica also recently received notice of allowance from the Mexican Patent Office for its initial InFoods IBS patent filed in that country.
  • The Biomerica InFoods IBS product is designed to allow physicians to identify patient-specific foods (e.g., eggs, broccoli, wheat, potatoes, pork, etc.
  • Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica.